Fragonomics: fragment-based drug discovery

被引：81

作者：

Zartler, ER ^{[1
]}

Shapiro, MJ ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2005年 / 9卷 / 04期

关键词：

D O I：

10.1016/j.cbpa.2005.05.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The use of smaller molecules (fragments) in the drug discovery process has led to success in delivering novel leads for many different targets. This process is a highly integrated process, starting from library design to screening and medicinal chemistry. An overview of this process is presented with particular emphasis placed on the NMR aspect of screening.

引用

页码：366 / 370

页数：5

共 42 条

[1] FUNCTIONAL-GROUP CONTRIBUTIONS TO DRUG RECEPTOR INTERACTIONS [J].

ANDREWS, PR ;

CRAIK, DJ ;

MARTIN, JL .

JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (12) :1648-1657

[2] A minimalist approach to fragment-based ligand design using common rings and linkers: Application to kinase inhibitors [J].

Aronov, AM ;

Bemis, GW .

PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2004, 57 (01) :36-50

[3] Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets [J].

Baurin, N ;

Aboul-Ela, F ;

Barril, X ;

Davis, B ;

Drysdale, M ;

Dymock, B ;

Finch, H ;

Fromont, C ;

Richardson, C ;

Simmonite, H ;

Hubbard, RE .

JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2004, 44 (06) :2157-2166

[4] High-throughput X-ray crystallography for drug discovery [J].

Blundell, TL ;

Patel, S .

CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (05) :490-496

[5] A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design [J].

Card, GL ;

Blasdel, L ;

England, BP ;

Zhang, C ;

Suzuki, Y ;

Gillette, S ;

Fong, D ;

Ibrahim, PN ;

Artis, DR ;

Bollag, G ;

Milburn, MV ;

Kim, SH ;

Schlessinger, J ;

Zhang, KYJ .

NATURE BIOTECHNOLOGY, 2005, 23 (02) :201-207

[6] Generation of a new class of hNK2 receptor ligands using the 'fragment approach' [J].

D'Andrea, P ;

Porcelloni, M ;

Madami, A ;

Patacchini, R ;

Altamura, M ;

Fattori, D .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (03) :585-588

[7] In situ assembly of enzyme inhibitors using extended tethering [J].

Erlanson, DA ;

Lam, JW ;

Wiesmann, C ;

Luong, TN ;

Simmons, RL ;

DeLano, WL ;

Choong, IC ;

Burdett, MT ;

Flanagan, WM ;

Lee, D ;

Gordon, EM ;

O'Brien, T .

NATURE BIOTECHNOLOGY, 2003, 21 (03) :308-314

[8] Fragment-based drug discovery [J].

Erlanson, DA ;

McDowell, RS ;

O'Brien, T .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) :3463-3482

[9] Molecular recognition: the fragment approach in lead generation [J].

Fattori, D .

DRUG DISCOVERY TODAY, 2004, 9 (05) :229-238

[10] Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach [J].

Fattorusso, R ;

Jung, DW ;

Crowell, KJ ;

Forino, M ;

Pellecchia, M .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) :1649-1656

← 1 2 3 4 5 →